Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1 6Phase 3 3Phase 1/2 1

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Tumor-Agnostic 3Other solid neoplasm 2CNS 1

Conditions

Neoplasms 3Brain Neoplasms 1Advanced Solid Tumors 1Advance Solid Tumors 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1 × iniparib × Clear all
NCT01551680 2025-02-13

RAPIBE

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 1 Terminated
3 enrolled
CNS

Brain Neoplasms

NCT00422682 2016-06-10

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

Sanofi

Phase 1 Completed
136 enrolled
Tumor-Agnostic

Neoplasms

NCT01455532 2014-10-22

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

NCT01161836 2013-09-24

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Sanofi

Phase 1 Completed
7 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT01213381 2013-05-24

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advance Solid Tumors

NCT00298675 2012-08-02

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

Sanofi

Phase 1 Completed
59 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡